On September 28 uniMIND Central Session will host Mauro Cavarra for an open discussion on our recently published paper reviewing the different models of psychedelic-assisted psychotherapy used in clinical trials. The session will start at 7pm (CEST) and anyone is welcome to join via the MIND Community Platform.
What do we mean when we say Psychedelic-Assisted Psychotherapy (PAP)? While some general guidelines to conduct PAP treatment programs are quite established and agreed upon, the degree of variability within the preparation - drug session - integration model is still very high. Our latest publication collects, compares and analyses the different therapeutic approaches that are… Continue reading Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
The therapeutic potential of psychedelics (psilocybin, LSD, DMT, ayahuasca) is increasingly shown by clinical studies and is proposed to result from increases in neuroplasticity - the brain’s ability to change throughout life. This systematic literature review summarizes the evidence that psychedelics induce neuroplasticity by focusing on psychedelics’ cellular and molecular neuroplasticity effects after single and repeated administration, as investigated in… Continue reading Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Kim Kuypers spoke with NPO Radio 1, about LSD, microdosing, and our ongoing microdosing trial. Listen to the podcast here.
BBC World Service, 24-8-2018 "LSD, magic mushrooms, mescaline, peyote - just some of the most well known psychedelic drugs. Most of them are illegal around the world. Research into psychedelic medicine was virtually shut down in the West because psychedelics were considered mind-altering substances open to abuse. This perception is changing. There is a growing body… Continue reading A New Perspective on Psychedelics
